A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 25 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.